Nkarta (NASDAQ:NKTX) Issues Earnings Results, Beats Expectations By $0.06 EPS

Nkarta (NASDAQ:NKTX) announced its quarterly earnings results on Wednesday. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.06, Zacks reports.

Nkarta Stock Performance

Shares of Nkarta stock opened at $1.97 on Friday. The company has a market cap of $139.02 million, a price-to-earnings ratio of -1.05 and a beta of 0.90. Nkarta has a one year low of $1.31 and a one year high of $11.84. The business’s 50 day moving average price is $2.00 and its 200 day moving average price is $2.89.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of Nkarta in a report on Thursday. HC Wainwright restated a “buy” rating and set a $18.00 price objective on shares of Nkarta in a research report on Thursday. Finally, Stifel Nicolaus cut their target price on Nkarta from $15.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday. Six investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $14.86.

Insider Transactions at Nkarta

In other news, CEO Paul J. Hastings sold 17,378 shares of Nkarta stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $2.20, for a total transaction of $38,231.60. Following the completion of the sale, the chief executive officer now directly owns 319,859 shares in the company, valued at $703,689.80. The trade was a 5.15 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 8.70% of the company’s stock.

About Nkarta

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.